Robert Berman Sells 25,000 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider Robert Berman sold 25,000 shares of the stock in a transaction on Monday, December 11th. The stock was sold at an average price of $21.28, for a total value of $532,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Robert Berman also recently made the following trade(s):

  • On Thursday, November 9th, Robert Berman sold 27,423 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $26.60, for a total value of $729,451.80.
  • On Tuesday, November 14th, Robert Berman sold 160,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $25.76, for a total value of $4,121,600.00.

Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) opened at $23.24 on Thursday. Biohaven Pharmaceutical Holding Co Ltd has a 12-month low of $17.00 and a 12-month high of $39.51.

Hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP purchased a new stake in Biohaven Pharmaceutical in the third quarter valued at about $302,000. Perceptive Advisors LLC purchased a new stake in Biohaven Pharmaceutical in the third quarter valued at about $11,443,000. Janus Henderson Group PLC purchased a new stake in Biohaven Pharmaceutical in the third quarter valued at about $25,751,000. VHCP Management II LLC purchased a new stake in Biohaven Pharmaceutical in the third quarter valued at about $60,826,000. Finally, Nicholas Investment Partners LP purchased a new stake in Biohaven Pharmaceutical in the third quarter valued at about $3,602,000. 47.76% of the stock is currently owned by institutional investors.

A number of equities analysts have recently issued reports on BHVN shares. Needham & Company LLC dropped their price target on Biohaven Pharmaceutical from $43.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, October 3rd. BidaskClub downgraded Biohaven Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 20th. Piper Jaffray Companies reissued a “buy” rating and set a $54.00 price target on shares of Biohaven Pharmaceutical in a research report on Tuesday, September 12th. Finally, Zacks Investment Research raised Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Monday, December 4th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $37.17.

TRADEMARK VIOLATION NOTICE: “Robert Berman Sells 25,000 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://weekherald.com/2017/12/14/robert-berman-sells-25000-shares-of-biohaven-pharmaceutical-holding-co-ltd-bhvn-stock.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply